These findings reveal that, given the role of cannabinoid receptors in diabetes pathophysiology, γ-Sanshool with a dual function on CB1 receptors inhibition in combination with CB2 activation may be useful in the treatment of diabetes. The gene discussed is CNR2; the disease is diabetes mellitus.